Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04844970 · ClinicalTrials.gov registry record · Phase 2
Anamorelin Study for Advanced Pancreatic Cancer
A Phase 2 study, sponsored by Lahey Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT04844970 is a Phase 2 study that was terminated before completion, run by Lahey Clinic. The registered enrollment target is 4 participants.
The verdict
NCT04844970, a Phase 2 study, was terminated before completion, sponsored by Lahey Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
Multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of anamorelin HCl. Approximately 100 subjects with advanced PDAC and cachexia will be randomized 1:1 to anamorelin HCl 100 mg or placebo, taken orally once daily (QD) for a total of 25 weeks. Subjects will be instructed to take the study drug at least 1 hour before their first meal of the day
Interventions
- DRUG Placebo
- DRUG Anamorelin Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2023-04-01 |
| Est. Completion | 2023-11-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04844970
The ClinicalTrials.gov registry entry for NCT04844970 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lahey Clinic, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04844970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04844970 about?
NCT04844970 is a clinical study titled "Anamorelin Study for Advanced Pancreatic Cancer". Multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of anamorelin HCl. Approximately 100 subjects with advanced PDAC and cachexia will be randomized 1:1 to anamorelin HCl 100 mg or placebo, taken orally once daily (QD) for a total of 25 weeks. Subjects...
What is the current status of trial NCT04844970?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2023-04-01. Estimated completion is 2023-11-07.
What interventions are being tested in trial NCT04844970?
The interventions under investigation include: Placebo (DRUG), Anamorelin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT04844970?
This trial is sponsored by Lahey Clinic, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.